BTB Therapeutics

BTB Therapeutics is a private, pre-clinical stage biotech leveraging a novel transcriptomics platform to discover small molecule drugs. Its lead program, BTB-101, is a non-opioid analgesic aimed at addressing the opioid crisis, while secondary programs target rare genetic diseases like Cardiac Fabry disease and Long QT syndrome via RNA splicing modulation. The company, founded on academic research from Kyoto University, recently re-domiciled to the US, positioning itself to access larger capital and pharmaceutical markets.

Transcriptomics-based drug discovery platform that identifies mechanisms of action and develops small molecules to intervene in the transcriptome, with a focus on RNA splicing regulation.

In non-opioid pain, BTB competes with numerous biopharma companies developing novel mechanisms (e.g., NaV1.7/1.8 inhibitors, NGF antibodies). In RNA splicing, it faces competition from both oligonucleotide-based therapies (e.g., from Ionis, Sarepta) and other small molecule splicing modifiers (e.g., from Novartis, Roche).